NEW YORK, April 7 /PRNewswire-FirstCall/ -- Global Pharmatech, Inc. (OTC PK: GBLP), a company which combines Traditional Chinese Medicine (TCM) based R&D, manufacturing and sales and marketing for the Over-the-Counter (OTC) and prescription drug market, is currently in the process of registering a company in New York to market Global Pharmatech's branded TCM-based products for distribution into the U.S. and other global markets outside of its existing core China and Southeast Asia presence.
In a recent trip to New York, Dr. Sun Xiaobo, President and CEO of Global Pharmatech Inc, remained positive on the Company's operations, stating, "With the combination of research, manufacture and sales, our wholly-owned subsidiary, Jilin Natural Pharmatech, is able to not only conduct R&D for its subsidiaries on new drugs with strong demand, but also do the same for domestic and international drug and dietary supplements companies. Furthermore, the Company will be able to manufacture these new products for both domestic and international companies. By establishing a physical presence in the U.S., Global Pharmatech will be able to leverage its R&D and production strength in China to further brand its TCM-based drug products overseas."
Through its wholly-owned subsidiary, Jilin Natural Pharmatech which houses R&D facilities, laboratories, and drug safety evaluation centers certified by the State Food and Drug Administration of China (SFDA), Global Pharmatech along with two drug manufacturing subsidiaries has been able to not only manufacture and sell the Company's own products, but also manufacture for other domestic as well as international drug companies. The Company has been looking to expand its research and product market to the United States and other global markets. Dr. Sun added, "We are excited to have a U.S. presence to facilitate distributor relationships and tap into the growing TCM export market."
ABOUT GLOBAL PHARMATECH
Global Pharmatech, through its subsidiaries, develops, manufactures and markets proprietary drugs that are based on Traditional Chinese Medicine while utilizing modern facilities and advanced R&D technologies. Global Pharmatech offers a full range of "start to finish" biotech services, from R&D and testing, to manufacturing drugs in liquid and solid dose forms, to sales and marketing. Global Pharmatech utilizes unique extraction methods and innovative techniques that have been developed by its R&D team. Global Pharmatech's core business to date has been licensing its R&D patents and technologies for botanical/biological drug products. Global Pharmatech's operations are currently based in the People's Republic of China with sales distribution in China, Malaysia, Singapore and Indonesia.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.
Contact: Brandi Piacente Investor Relations The Anne McBride Co. 212-983-1702 x208 Email: bpiacente@annemcbride.com
Global Pharmatech, Inc.CONTACT: Brandi Piacente, Investor Relations, The Anne McBride Co.,+1-212-983-1702 ext. 208, bpiacente@annemcbride.com, for Global Pharmatech,Inc.
